White Rose University Consortium logo
University of Leeds logo University of Sheffield logo York University logo

Diagnosis and management of early inflammatory arthritis

Nam, Jacqueline Leong (2015) Diagnosis and management of early inflammatory arthritis. PhD thesis, University of Leeds.

Nam_JL_Medicine_PhD_2015.pdf - Final eThesis - complete (pdf)
Available under License Creative Commons Attribution 2.0 UK: England & Wales.

Download (3751Kb) | Preview


Rheumatoid arthritis (RA) represents a disease continuum from the pre-clinical period, through undifferentiated inflammatory arthritis (IA) to early then established RA. Improved patient outcomes in recent years reflect early diagnosis, prompt disease-modifying anti-rheumatic drug (DMARD) therapy, treat-to-target strategies and use of biological therapies (bDMARDs) particularly following failure of conventional synthetic therapies (csDMARDs). Optimal use of bDMARDs in early disease, however, has not been established. Early detection in the pre-clinical stage is potentially achievable with modern diagnostics but understanding of how to use these biomarkers is lacking. A systematic literature review on the use of bDMARDs was performed and confirmed the efficacy of bDMARDs in patients with established RA. Few studies were found addressing their use in early disease. Two randomised controlled trials were performed to explore early bDMARD intervention. The first, in early DMARD-naïve RA, compared methotrexate and infliximab to methotrexate and high-dose intravenous methylprednisolone as induction therapy, followed by a treat-to-target strategy; both arms demonstrated efficacy with no significant between-group differences. In the second, early DMARD naïve IA patients treated with combination etanercept and methotrexate had earlier clinical improvement than methotrexate monotherapy; however both groups achieved good 12 month outcomes. In a longitudinal cohort study conducted in secondary care, 50% of patients with musculoskeletal (MSK) symptoms and anti-cyclic citrullinated peptide (anti-CCP) antibodies progressed to clinical IA. Use of additional biomarkers including rheumatoid factor, shared epitope and ultrasound enabled further risk stratification for progression. In a primary care cohort, the anti-CCP antibody was positive in 2.8% with new nonspecific MSK symptoms with almost half progressing to IA. In summary, in early DMARD naïve IA, use of bDMARD may not be superior to csDMARDs with a treat-to-target approach. In patients with MSK symptoms, anti-CCP testing identifies individuals at risk of developing IA; additional biomarkers improve prediction and are feasible for clinical use.

Item Type: Thesis (PhD)
Related URLs:
Keywords: inflammatory arthritis, rheumatoid arthritis, biologic, DMARD, anti-CCP, ultrasound, systematic literature review
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Musculoskeletal Disease (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds)
Identification Number/EthosID: uk.bl.ethos.675526
Depositing User: Dr Jacqueline L Nam
Date Deposited: 23 Dec 2015 15:18
Last Modified: 26 Apr 2016 15:44
URI: http://etheses.whiterose.ac.uk/id/eprint/11435

You do not need to contact us to get a copy of this thesis. Please use the 'Download' link(s) above to get a copy.
You can contact us about this thesis. If you need to make a general enquiry, please see the Contact us page.

Actions (repository staff only: login required)